{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:26:42Z","timestamp":1760920002918,"version":"build-2065373602"},"reference-count":19,"publisher":"Wiley","issue":"12Part2","license":[{"start":{"date-parts":[[1991,12,1]],"date-time":"1991-12-01T00:00:00Z","timestamp":691545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lipids"],"published-print":{"date-parts":[[1991,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The selective hetrazepinoic platelet\u2010activating factor (PAF) antagonist WEB 2170 (Bepafant) was used to study the pathophysiological role of PAF in several models of anaphylaxis in mice and guinea pigs. In actively sensitized mice, the PAF antagonist WEB 2170 (1.0\u201310 mg\/kg<jats:italic>p.o.<\/jats:italic>) protected mice from anaphylactic death in a dosedependent manner when the anaphylactic response was potentiated by the beta\u2010receptor antagonist propranolol. When active anaphylaxis in guinea pigs was induced intravenously by 100 mg\/kg ovalbumin (OA) in the presence of small doses of the antihistamine mepyramine, additional treatment with oral or intravenous WEB 2170 protected the guinea pigs from anaphylactic death. Also, the remaining anaphylactic bronchoconstriction and blood pressure changes (including anaphylactic hypotension) were attenuated. When guinea pigs were passively sensitized with a heterologous antibody<jats:italic>via<\/jats:italic> the tracheal route and then challenged by ovalbumin (100 mg\/kg<jats:italic>i.v.<\/jats:italic>) 24 hr after sensitization in the presence of 0.003 mg\/kg<jats:italic>i.v.<\/jats:italic> mepyramine, additional treatment with tracheal WEB 2170 at 0.1\u20131 mg\/kg protected the guinea pigs dosedependently not only from anaphylactic death but also from a further decrease of respiratory flow and changes of blood pressure. Increased levels of PAF\u2010like activity (20\u201350 ng PAF\/whole lung) were detected in lungs removed from antigen\u2010challenged animals. The results suggest a causative role for PAF in active and passive anaphylaxis.<\/jats:p>","DOI":"10.1007\/bf02536570","type":"journal-article","created":{"date-parts":[[2007,2,3]],"date-time":"2007-02-03T20:35:06Z","timestamp":1170534906000},"page":"1374-1380","source":"Crossref","is-referenced-by-count":2,"title":["Effect of the hetrazepinoic platelet\u2010activating factor antagonist bepafant (WEB 2170) in models of active and passive anaphylaxis in mice and guinea pigs"],"prefix":"10.1002","volume":"26","author":[{"given":"H. O.","family":"Heuer","sequence":"first","affiliation":[{"name":"Department of Pharmacology Boehringer Ingelheim KG Ingelheim\/Rhein W\u20106507 Germany"},{"name":"Department of Pharmacology Boehringer Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road Ridgefield CT P.O. Box 36806877\u20100368"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[1991,12]]},"reference":[{"key":"e_1_2_2_2_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3082008"},{"key":"e_1_2_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0090-6980(87)90011-6"},{"key":"e_1_2_2_4_1","first-page":"271","volume-title":"Ginkgolides. Chemistry, Biology, Pharmacology and Clinical Perspectives","author":"Desquand S.","year":"1988"},{"key":"e_1_2_2_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1988.tb11496.x"},{"key":"e_1_2_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(87)90288-3"},{"key":"e_1_2_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0162-3109(87)90048-8"},{"key":"e_1_2_2_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02142542"},{"key":"e_1_2_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0031-6989(86)90129-3"},{"key":"e_1_2_2_10_1","first-page":"A1577","volume":"2","author":"Lohman I.C.","year":"1988","journal-title":"FASEB J."},{"key":"e_1_2_2_11_1","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0022-3565(25)23219-0","volume":"255","author":"Heuer H.O.","year":"1990","journal-title":"J. Pharmacol. Exper. Ther."},{"key":"e_1_2_2_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1980.tb01718.x"},{"key":"e_1_2_2_13_1","doi-asserted-by":"publisher","DOI":"10.1139\/y59-099"},{"key":"e_1_2_2_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02536571"},{"key":"e_1_2_2_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1987.tb16841.x"},{"key":"e_1_2_2_16_1","first-page":"850","volume":"35","author":"Heuer H.","year":"1988","journal-title":"Prostaglandins"},{"key":"e_1_2_2_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01971477"},{"key":"e_1_2_2_18_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/138.6.1572"},{"key":"e_1_2_2_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1990.tb15785.x"},{"key":"e_1_2_2_20_1","first-page":"39","volume":"4","author":"Heuer H.O.","year":"1991","journal-title":"J. Lipid Mediators"}],"container-title":["Lipids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aocs.onlinelibrary.wiley.com\/doi\/pdf\/10.1007\/BF02536570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T10:16:50Z","timestamp":1760869010000},"score":1,"resource":{"primary":{"URL":"https:\/\/aocs.onlinelibrary.wiley.com\/doi\/10.1007\/BF02536570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,12]]},"references-count":19,"journal-issue":{"issue":"12Part2","published-print":{"date-parts":[[1991,12]]}},"alternative-id":["10.1007\/BF02536570"],"URL":"https:\/\/doi.org\/10.1007\/bf02536570","archive":["Portico"],"relation":{},"ISSN":["0024-4201","1558-9307"],"issn-type":[{"type":"print","value":"0024-4201"},{"type":"electronic","value":"1558-9307"}],"subject":[],"published":{"date-parts":[[1991,12]]}}}